Dr G R Reyes joins Benitec as Senior Scientific Advisor
Benitec Biopharma Limited, a Sydney based clinicalstage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, recently announced that Gregory R. Reyes, M.D., Ph.D., has joined the company as Senior Scientific Advisor. As the Senior Scientific Advisor, Dr Reyes will lead the company’s efforts to advance and expand its portfolio of gene therapy products. His leadership and vision will be integral to the achievement of the operational and strategic goals regarding the Company’s key indications and research programmes. Dr Reyes will also oversee the expansion of the company’s scientific operations to facilitate the successful execution of the Company’s broad based research collaboration with Axovant, comprising five additional, fully funded research programmes targeting neurological disorders. Dr Reyes brings over 30 years of successful R&D leadership experience in major biotechnology and pharmaceutical companies.